Potential Sciences, a British startup working on AI-driven design of new medicines, has secured backing from the UK Government's Sovereign AI venture fund as part of an eight-figure funding round announced on Thursday 5 November 2026. The support includes investment and access to compute through the AI Research Resource, the UK's national suite of advanced supercomputers, including the Isambard-AI supercomputer in Bristol.

The company's approach centres on an AI model built around the fundamental laws of physics rather than previous experimental data. According to the government press release, this could make the AI calculations needed to design chemicals 100 times cheaper than at present. The announcement cites cancer and Parkinson's as diseases where new drug design approaches could offer hope, while noting that progress has been held back by reliance on slow, costly real-world lab experiments.

Sovereign AI is the government's venture fund for early-stage AI companies, with typical equity investments of around £1-10 million. Other backers in the round include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital and Lightfield Equity, alongside angel investors including Patrick Collison and Chris Gibson. AI Minister Kanishka Narayan and Science Minister Chris McDonald both welcomed the investment. The release also notes that, a week earlier, the Chancellor confirmed a further £140 million for Sovereign AI, with an additional £60 million to support the fund's investments and £80 million for its R&D Procurement Scheme.